COMMUNIQUÉS West-GlobeNewswire

DiagnaMed Announces LIFE Offering of up to $650,000

16/05/2024 - 00:10

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is pleased to announce that [...]

Spectral AI Announces Voting Results from 2024 Annual Meeting of Stockholders and the Appointment of Erich Spangenberg to the Board of Directors

16/05/2024 - 00:05

DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

16/05/2024 - 00:00

Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, [...]

CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights

15/05/2024 - 23:17

Reported Full Year 2023 total revenues of 2% growth at €48.5 million Secured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the PIF [...]

Range Impact Reports 1Q 2024 Financial Results

15/05/2024 - 23:15

CLEVELAND, OHIO, May 15, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in Appalachia, reported [...]

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

15/05/2024 - 23:13

Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results [...]

Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update

15/05/2024 - 23:11

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of [...]

CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position

15/05/2024 - 23:10

Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science [...]

Extendicare Announces 2024 First Quarter Results

15/05/2024 - 23:00

MARKHAM, Ontario, May 15, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three months ended March 31, 2024. Results are presented in Canadian dollars [...]

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15/05/2024 - 23:00

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering [...]

Profound Medical Annual General Meeting of Shareholders Voting Results

15/05/2024 - 23:00

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General Meeting of Shareholders that was [...]

Quipt Home Medical Reports Second Quarter Fiscal 2024 Financial Results Posting Revenue Growth of 10% and Adjusted EBITDA Growth of 14%

15/05/2024 - 23:00

• Posts Adjusted EBITDA Margin of 23.3% as a % of Revenue • Announced Normal Course Issuer Bid (“NCIB”) Subsequent to Quarter End CINCINNATI, May 15, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) ( [...]

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

15/05/2024 - 23:00

Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA™ (bevacizumab gamma) United Kingdom (UK) Marketing Authorization [...]

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

15/05/2024 - 23:00

IND clearance for GTB-3650, a 2 nd generation nanobody TriKE ® for treatment of CD33+ leukemia expected in Q2 2024 Phase 1 trial initiation with GTB-3650 expected in 2H 2024 Anticipate IND submission for GTB-5550 TriKE [...]

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

15/05/2024 - 22:39

MIRAMAR, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel [...]

FibroBiologics Announces 2024 Annual Meeting of Stockholders

15/05/2024 - 22:30

HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of [...]

Precision Optics Reports Third Quarter Fiscal Year 2024 Financial Results

15/05/2024 - 22:30

Conference Call Scheduled for today, May 15, 2024, at 5:00pm ET GARDNER, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical [...]

NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024

15/05/2024 - 22:30

CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15/05/2024 - 22:30

ELI-002 2P Phase 1 preliminary data published in Nature Medicine ELI-002 2P Phase 1 data characterizing the CD4 and CD8 profile of the KRAS immune response and ELI-002-generated antigen spreading presented at the AACR [...]